CC-Chemokine Receptor-2 Expression in Osteoblasts Contributes to Cartilage and Bone Damage during Post-Traumatic Osteoarthritis

Public Deposited
Analytics

Downloadable Content

Download PDF
Request Version for Screen Reader
Creator
  • Willcockson, Helen
    • Affiliation: School of Medicine, Division of Rheumatology, Allergy and Immunology
  • Ozkan, Huseyin
    • Affiliation: School of Medicine, Division of Rheumatology, Allergy and Immunology
  • Valdés-Fernández, José
    • Other Affiliation: Universidad de Navarra
  • Arbeeva, Liubov
    • Affiliation: School of Medicine, Division of Rheumatology, Allergy and Immunology
  • Mucahit, Esra
    • Affiliation: School of Medicine, Division of Rheumatology, Allergy and Immunology
  • Musawwir, Layla
    • Affiliation: School of Medicine, Division of Rheumatology, Allergy and Immunology
  • Hooper, Lola B.
    • Affiliation: School of Medicine, Division of Rheumatology, Allergy and Immunology
  • Granero-Moltó, Froilán
    • Other Affiliation: Universidad de Navarra
  • Prósper, Felipe
    • Other Affiliation: Universidad de Navarra
  • Longobardi, Lara
    • Affiliation: School of Medicine, Division of Rheumatology, Allergy and Immunology
Abstract
  • In osteoarthritis (OA), bone changes are radiological hallmarks and are considered important for disease progression. The C-C chemokine receptor-2 (CCR2) has been shown to play an important role in bone physiology. In this study, we investigated whether Ccr2 osteoblast-specific inactivation at different times during post-traumatic OA (PTOA) progression improves joint structures, bone parameters, and pain. We used a tamoxifen-inducible Ccr2 inactivation in Collagen1α-expressing cells to obtain osteoblasts lacking Ccr2 (CCR2-Col1αKO). We stimulated PTOA changes in CCR2-Col1αKO and CCR2+/+ mice using the destabilization of the meniscus model (DMM), inducing recombination before or after DMM (early- vs. late-inactivation). Joint damage was evaluated at two, four, eight, and twelve weeks post-DMM using multiple scores: articular-cartilage structure (ACS), Safranin-O, histomorphometry, osteophyte size/maturity, subchondral bone thickness and synovial hyperplasia. Spontaneous and evoked pain were assessed for up to 20 weeks. We found that early osteoblast-Ccr2 inactivation delayed articular cartilage damage and matrix degeneration compared to CCR2+/+, as well as DMM-induced bone thickness. Osteophyte formation and maturation were only minimally affected. Late Collagen1α-Ccr2 deletion led to less evident improvements. Osteoblast-Ccr2 deletion also improved static measures of pain, while evoked pain did not change. Our study demonstrates that Ccr2 expression in osteoblasts contributes to PTOA disease progression and pain by affecting both cartilage and bone tissues.
Date of publication
Keyword
DOI
Identifier
Resource type
  • Article
Rights statement
  • In Copyright
License
  • Attribution 4.0 International
Journal title
  • Biomolecules
Journal volume
  • 13
Journal issue
  • 6
Page start
  • 891
Language
  • English
Version
  • Publisher
ISSN
  • 2218-273X
Publisher
  • MDPI

Relations

Parents:

This work has no parents.

In Collection:

Items

Thumbnail Title Date Uploaded Visibility Actions
file details biomolecules-13-00891-v2.pdf 2023-06-08 Public Download